Animal models for IgE-meditated cancer immunotherapy
- 23 December 2011
- journal article
- research article
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 61 (9) , 1535-1546
Abstract
Although most monoclonal antibodies developed for cancer therapy are of the IgG class, antibodies of the IgE class have certain properties that make them attractive as cancer therapeutics. These properties include the superior affinity for the Fc epsilon receptors (FcεRs), the low serum level of IgE that minimizes competition of endogenous IgE for FcεR occupancy, and the ability to induce a broad and vigorous immune response through the interaction with multiple cells including mast cells, basophils, monocytes, macrophages, dendritic cells, and eosinophils. Tumor-targeted IgE antibodies are expected to harness the allergic response against tumors and activate a secondary, T-cell-mediated immune response. Importantly, the IgE antibody can be used for passive immunotherapy and as an adjuvant of cancer vaccines. However, there are important limitations in the use of animal models including the fact that human IgE does not interact with rodent FcεRs and that there is a different cellular distribution of FcεRs in humans and rodents. Despite these limitations, different murine models have been used with success to evaluate the in vivo anti-cancer activity of several IgE antibodies. These models include wild-type immunocompetent animals bearing syngeneic tumors, xenograft models using immunocompromised mice bearing human tumors and reconstituted with human effector cells, and human FcεRIα transgenic mice bearing syngeneic tumors. In addition, non-human primates such as cynomolgus monkeys can be potentially used for toxicological and pharmacokinetic studies. This article describes the advantages and disadvantages of these models and their use in evaluating the in vivo properties of IgE antibodies for cancer therapy.Keywords
This publication has 71 references indexed in Scilit:
- Targeting HER2/neu with a fully human IgE to harness the allergic reaction against cancer cellsCancer Immunology, Immunotherapy, 2011
- Antibody-Dependent Natural Killer Cell–Mediated Cytotoxicity Engendered by a Kinase-Inactive Human HER2 Adenovirus-Based Vaccination Mediates Resistance to Breast TumorsCancer Research, 2010
- The antigen presentation function of bone marrow-derived mast cells is spatiotemporally restricted to a subset expressing high levels of cell surface FcεRI and MHC IIBMC Immunology, 2010
- A 4-Week Intrathecal Toxicity and Pharmacokinetic Study With Trastuzumab in Cynomolgus MonkeysInternational Journal of Toxicology, 2010
- Expression of human cytokines dramatically improves reconstitution of specific human-blood lineage cells in humanized miceProceedings of the National Academy of Sciences, 2009
- Antitumor IgE Adjuvanticity: Key Role of FcεRIThe Journal of Immunology, 2009
- Utility of Serum HER2 Extracellular Domain Assessment in Clinical Decision Making: Pooled Analysis of Four Trials of Trastuzumab in Metastatic Breast CancerJournal of Clinical Oncology, 2009
- Oregovomab Maintenance Monoimmunotherapy Does Not Improve Outcomes in Advanced Ovarian CancerJournal of Clinical Oncology, 2009
- AllergoOncology: the role of IgE‐mediated allergy in cancerAllergy, 2008
- ERBB receptors and cancer: the complexity of targeted inhibitorsNature Reviews Cancer, 2005